For the year ending 2025-12-31, RNAC has $296,411K in assets. $422,651K in debts. $125,139K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 125,139 | |||
| Accounts receivable | 1,115 | |||
| Prepaid expenses and other current assets | 3,022 | |||
| Total current assets | 129,276 | |||
| Property and equipment, net | 12,185 | |||
| Right-of-use assets, net | 5,601 | |||
| In-process research and development assets | 93,900 | |||
| Goodwill | 48,163 | |||
| Long-term restricted cash | 1,735 | |||
| Investment | 0 | |||
| Long-term prepaid expenses and other assets | 5,551 | |||
| Total assets | 296,411 | |||
| Accounts payable | 1,288 | |||
| Accrued expenses and other current liabilities | 9,498 | |||
| Lease liabilities | 4,151 | |||
| Contingent value right liability | 0 | |||
| Total current liabilities | 14,937 | |||
| Lease liabilities, net of current portion | 8,525 | |||
| Warrant liability | 141 | |||
| Contingent value right liability, net of current portion | 392,100 | |||
| Deferred tax liabilities, net | 6,948 | |||
| Total liabilities | 422,651 | |||
| Preferred stock, value, issued-Series APreferred Stock | 0 | |||
| Preferred stock, value, issued-Series BPreferred Stock | 0 | |||
| Preferred stock, value, issued | 0 | |||
| Common stock, 0.0001 par value 350,000,000 shares authorized as of december 31, 2025 and 2024 26,011,106 and 25,767,369 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 3 | |||
| Additional paid-in capital | 700,706 | |||
| Accumulated deficit | -822,373 | |||
| Accumulated other comprehensive loss | -4,576 | |||
| Total stockholders deficit | -126,240 | |||
| Total liabilities and stockholders deficit | 296,411 | |||
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)